1IL aurie H. Sehn. Joseph M. Connors,et al. Treatment of Aggressive Non - Hoddgkin' s Lynnphoma:A North American Perspective. Oneology, 2005,19 ( 4 ) : Supplement. 被引量：1
3Landis SH. Murray T. Bolden S, et al. Cancer statistics. 1999. CA Canccr J Clin. 1999 Jan - Feb :49( 1 ) : 8 -31. 被引量：1
4Bubien JK, Zhou L J, Bell PD, et al. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2 + conductance found constitutively in B lymphocvtes. J Cell Biol, 1993 Jun: 121 (5) : 1121 -32. 被引量：1
5Leveill C. Al - Daccak R. Mound W. CD20 is physically and functionally coupled to MHC class Ⅱ and CD40 on human B cell lines. Eur J Immunol. 1999 Jan ;29 ( 1 ) :65 - 74. 被引量：1
2[1]Goss PE. New perspectives in the treatment of non-Hodgkin's lymphoma.Semin Oncol, 1992; 19:23～30 被引量：1
3[2]Goss PE, Shepherd FA, Scott JG, et al.Dexamethasone/ifosfamide/cisplatin/etoposide(DICE) as therapy for patients with advanced refractory non-Hodgkin's lymphoma:preliminary report of a phase Ⅱ study. Ann Oncol, 1991 ;2 Suppl 1:43～46 被引量：1
4[3]Coleman M, Leonard J, Shuster MW, et al,DICE (dexamethasone, ifosfamide,cisplatin, etoposide)in fusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma(NHL).Eur J Haematol Suppl, 2001 (64):41～45 被引量：1
5[4]Inoue R, Natazuka T, Shimoyama M, et al. Feasibility of high-dose chemotherapy without stem cell support as a first-line treatment for non-Hodgkin's aggressive lymphoma:a pilot study. Leuk Lymphoma ,2000;36(3～4):315～321 被引量：1
6Maloney D G, Smith B, Rose A. Rituximab: mechanism of action and resistance [J]. Semin Oncol, 2002,29(1 Suppl 2):2-9. 被引量：1
7Wilson W H, Gutierrez M, O'Connor P, et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose- adjusted EPOCH - R[J].Semin Oncol, 2002,29(1 Suppl 2):41-47. 被引量：1
8Czuczman M S, Fallon A, Mohr A, et al.Rituximab in combination with CHOP or fludarabine in low-grade lymphoma [J].Semin Oncol, 2002,29(I Suppl 2):36-40. 被引量：1
9Lamonica D,Czuczman M,Nabi H,et al.Radioimmunoscintigraphy(RIS) with bectumomab(Tc99m labeled IMMU-LL2,lymphoscan) in the assessment of recurrent non-Hodgkin's lymphoma (NHL)[J].Cancer Biother Radiopharm,2002,6(17):689-697. 被引量：1
10Hainsworth JD,Burris HA, Morrissey LH. J Clin Oncol, 1999,17(1):268 被引量：1
